Phase I-II Study of Association of Deferasirox, Vitamin D and Azacytidine as Treatment of High Risk MDS (IPSS Int-2 and High)
Phase of Trial: Phase I/II
Latest Information Update: 22 Nov 2017
At a glance
- Drugs Deferasirox (Primary) ; Azacitidine; Colecalciferol
- Indications Myelodysplastic syndromes
- Focus Adverse reactions
- 11 Jul 2017 Planned End Date changed from 1 Feb 2018 to 1 Feb 2019.
- 11 Jul 2017 Planned primary completion date changed from 1 Feb 2017 to 1 Feb 2019.
- 27 Oct 2015 Planned End Date changed from 1 Nov 2015 to 1 Feb 2018 as reported by ClinicalTrials.gov record.